Oral LAT8881 in Neuropathic Pain
A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain
Sponsor: Lateral Pharma Pty Ltd
This PHASE2 trial investigates Diabetic Peripheral Neuropathy (DPN) and Neuropathic Pain and is currently completed. Lateral Pharma Pty Ltd leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Completed PHASE2
-
May 2021 — Jun 2021 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
May 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Aug 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Lateral Pharma Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .